Loading…
Pharmaceuticals · NSE · period ending 2026-03-31
Loading chart…
✓ Core business is permissible and non-compliant income is 0% of revenue (limit 5%).
| Ratio | Value | Limit | Result |
|---|---|---|---|
| Debt / 36-month avg market cap | 0% | < 33% | Pass |
| Cash + interest-bearing securities / 36-month avg market cap | 0% | < 33% | Pass |
| Accounts receivable / 36-month avg market cap | 0% | < 33% | Pass |
The underlying figures and the filing citations they came from are available with a free account.
Sign up free0% of any dividend from LUPIN should be given to charity. Calculate your amount →
Compliance watch: verdict re-verified against live market cap on 13 Jun 2026 · rechecked every 6 hours · filings reviewed quarterly.
The stock has modestly positive 6-month performance, slightly negative 3-month and small positive 1-month returns, with 50-day above 200-day and price around 7% off the 52-week high, suggesting a sideways-to-mildly-positive range. The mix of small gains and losses indicates consolidation rather than a decisive trend.
Computed from delayed price history and desk sentiment. Educational context only — not investment advice or a price prediction.